PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Microbiology, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.\', \'Department of Medical Statistics, Osaka City University Graduate School of Medicine, Osaka, Osaka, Japan.\', \'Department of Infectious Diseases, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.\', \'Department of Virology and Parasitology, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.\', \'Department of Virology and Parasitology, Fujita Health University School of Medicine, Toyoake, Aichi, Japan; Center for Joint Research Facilities Support, Research Promotion and Support Headquarters, Fujita Health University, Toyoake, Aichi, Japan.\', \'Department of Virology I, National Institute of Infectious Diseases, Shinjuku, Tokyo, Japan.\', \'Department of Microbiology, Fujita Health University School of Medicine, Toyoake, Aichi, Japan; Department of Infectious Diseases, Fujita Health University School of Medicine, Toyoake, Aichi, Japan; Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. Electronic address: yoheidoi@fujita-hu.ac.jp.\']
?:citedBy
  • -1
?:creator
?:doi
  • S1341-321X(21)00171-910.1016/j.jiac.2021.06.010
?:doi
?:hasPublicationType
?:journal
  • Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
is ?:pmid of
?:pmid
?:pmid
  • 34176716
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • Virological and genomic analysis of SARS-CoV-2 from a favipiravir clinical trial cohort.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all